VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Results of Operations and Financial ConditionITEM 2.02RESULTS OF OPERATION AND FINANCIAL CONDITION
ITEM 7.01REGULATION FD DISCLOSURE
On September 24, 2018 Vitro Diagnostics, Inc. (OTCQB: VODG) (the “Company”) issued a press release announcing a record in Stem Cell Revenues for 3rd quarter ended July 31, 2018. The Company recorded 3rd quarter revenues of $141,783 vs $64,566, an increase of 220% over the same comparative quarter last year. A copy of the Press Release is filed herewith as Exhibit 99.1.
The information in this Current Report on Form 8-K furnished to Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current Report on Form 8-K and furnishing this information to Item 7.01, The Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.
ITEM 9.01:EXHIBITS
|
Item |
Title |
|
99.1 |
Press Release |
VITRO DIAGNOSTICS INC ExhibitEX-99.1 2 vitro_99ez1.htm PRESS RELEASE Vitro Biopharma 3rd Quarter 2018 Financial Results of Operations Golden,…To view the full exhibit click here
About VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG)
Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.
